Voro and Alloy partner on tumour-selective TCE therapeutics
The new arrangement between Voro and Alloy centres on finding approaches that may enhance the therapeutic index of TCE therapies.
Drug Development
Biogen to acquire RayThera for up to $1bn
Jazz and AbCellera sign deal for T-cell engagers in solid tumours
LG AI Research and D&D Pharmatech sign agreement for oral peptide drugs
AviadoBio broadens vMiX gene silencing licence with King’s College London
Zai Lab’s zocilurtatug pelitecan secures EMA orphan drug status
Alkermes’ alixorexton secures FDA and EC orphan designations
Simcere and Stanford partner to develop IPF therapies
